Orchestra BioMed (NASDAQ:OBIO) traded higher on Friday after the company announced an FDA-approved protocol update that is ...

FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the ...

A phase III trial of baxdrostat for primary aldosteronism is now underway. Developer AstraZeneca is also testing it as ...

Researchers have found that renal denervation in patients with hypertension is associated in significant improvements in systolic blood pressure.

Patients without prior antihypertensive treatment or who had discontinued antihypertensive agents for two weeks were randomly assigned to the morning (6 a.m. to 10 a.m.) or bedtime (6 p.m. to 10 p ...

Patients who used combinations of cardiovascular therapies experienced slower cognitive decline and fewer neuropathologies ...

Delays in diagnosis of hypertension are common and associated with delays in treatment initiation, according to a study published online.

Better control of nocturnal blood pressure and improved circadian rhythm seen with bedtime versus daytime dosing.